Company: KROS
Filing Date: 2025-05-19
Form Type: DEFA14A
Source: 0001104659-25-050243
Chunk: 3

Company: Keros Therapeutics, Inc.
Filing Date: 2025-05-19
Form: DEFA14A
Chunk 3
---
 matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “anticipates,” “believes,” “continue,” “expects,” “enable,” “potential” and “will” or similar expressions are intended to identify forward-looking statements. Examples of these forward-looking statements include statements concerningthe
Annual Meeting and our director nominees. Because such statements are subject to risks and uncertainties, actual results may differ materially
from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others, the risk that
circumstances surrounding or leading up to our Annual Meeting may change; uncertainties regarding actions that have been taken and may
in the future be taken by ADAR1 relating to the Annual Meeting or otherwise, and potential costs and management distraction attendant
thereto; and other risks are described more fully in Keros’ filings with the SEC, including the “Risk Factors” section
of the Company’s Quarterly Report Form 10-Q, filed with the SEC on May 6, 2025, and its other documents subsequently filed
with or furnished to the SEC. All forward-looking statements contained in this Supplement speak only as of the date on which they were
made. Except to the extent required by law, Keros undertakes no obligation to update such statements to reflect events that occur or circumstances
that exist after the date on which they were made.

Additional Information Regarding the Annual Meeting of Shareholders and Where to Find It

Keros has filed the Proxy Statement with the SEC
with respect to its solicitation of proxies for the Annual Meeting.

STOCKHOLDERS ARE STRONGLY URGED TO READ CAREFULLY
AND IN THEIR ENTIRETY THE PROXY STATEMENT (INCLUDING THIS SUPPLEMENT AND ANY OTHER AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT
DOCUMENTS TO BE FILED WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT ANY SOLICITATION.

Stockholders may obtain a copy of the Proxy Statement
and any amendments or supplements to the Proxy Statement and any other relevant documents filed by the Company with the SEC at no charge
at the SEC’s website at www.sec.gov. Copies will also be available at no charge at the Company’s website at https://ir.kerostx.com/financials-filings/sec-filings.

Certain Information Regarding Participants

The Company, its directors